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Summary
Objective: To determine the in vivo effects of intraarticular MMP-13.
Methods: Human recombinant MMP-13 was injected intraarticularly (i.a.) into the hamster knee joint. MMP-13 activity, collagen and
proteoglycan fragments, and hyaluronan were measured in synovial fluid. Antibody 9A4 was used to localize collagen damage. Western
blotting was used to determine the size of type II collagen fragments.
Results: MMP-13 activity measurements showed greater than 98% of MMP-13 to be cleared instantly from the joint cavity. The remainder
was cleared with a t1/2 of 2 h. Immunohistochemical staining demonstrated collagen cleavage was limited to a thin superficial band on the
surface of the articular cartilage whereas collagen damage extended more deeply into the synovial capsule and the menisci. The elevation
of proteoglycan and hyaluronan in synovial fluid after MMP-13 was modest. Collagen fragments appeared in synovial fluid within 15 min
following MMP-13. They were cleared with a half-life of circa 1.8 h and the predominant fragment was 32 kDa.
Conclusions: Activated MMP-13 leads to tissue collagen damage with the release of collagen fragments. These fragments are measurable
and could provide a method for assessment of cartilage collagen damage. © 2000 OsteoArthritis Research Society International
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Collagenase 3 (MMP-13) is a well-characterized matrix
metalloproteinase with the capacity to cleave type II
collagen into a 3/4 fragment and a 1/4 fragment at a rate 10
times faster than MMP-1.1–3 MMP-13 has been shown to
be expressed in articular cartilage during osteoarthritis
(OA)3–7 and in the synovium of patients with rheumatoid
arthritis (RA).8,9 In vitro, evidence of MMP-13 involvement
in cleavage of type II collagen in osteoarthritic cartilage
has been obtained using an MMP-13 inhibitor.7 In vivo,
MMP-13 message has been localized in the lesional sites
of knee cartilage from guinea-pigs with a spontaneously
occurring OA, and the neoepitope of collagenase-cleaved
type II collagen was co-localized with the collagenase.10
This suggests that MMP-13 degrades type II collagen in
both human OA and animal models of OA. Nonetheless,
the role of MMP-13 in the etiology and pathology of
OA remains to be fully characterized. Some insight into
the potential role of MMP-13 has been obtained by
examining its activity against cartilage and type II collagen
in vitro.2–4,7,11–13 Here we attempt to refine our under-
standing of the impact of MMP-13 by direct examination
of its effects on cartilage in vivo after intraarticular
administration.
Collagenase cleaves the collagen triple helix between
amino acids glycine 774 and leucine 775 in type II collagen,
and between glycine 775 and isoleucine 776 in the type I
alpha 1 chain. An antibody that would detect the type I366and type II carboxy-terminal sequences —GPOGPQG,
—GPPGPQG and —GTPGPQG, while failing to detect
the intact collagens, could serve to identify the action of
collagenase in the tissue. The monoclonal antibody,
9A4, recognizes the collagen neoepitope generated by
collagenase in both type I and type II collagens.14 We have
used this antibody to demonstrate the appearance of
collagenase cleavage in articular cartilage of animals
undergoing an acute inflammation,14 in spontaneous
guinea-pig OA,10 and in murine collagen arthritis.15 We
have used this antibody in combination with another
monoclonal antibody, 5109,16 to track the appearance of
type II collagen fragments in synovial fluid. Using these
two antibodies in combination with measurements of
synovial fluid MMP-13 enzymatic activity and collagenase
tissue localization, we construct a picture of the possible
consequences of MMP-13 in vivo.Materials and methods
MATERIALS
Peptides, including the substrate TNO211, were syn-
thesized by Anaspec (San Jose, CA, U.S.A.). They were
purified to a single peak on HPLC and the structures
confirmed by mass spectroscopy. Recombinant human
collagenase 3 (MMP-13) and collagenase 1 (MMP-1) were
a gift from Peter Mitchell.3 Murine monoclonal antibodies to
the C-terminal collagen neoepitope, GPPGPQG, desig-
nated as 9A4,14 and to the sequence GEPGDDGPS,
designated as 5109,16 were prepared in our laboratories.Address correspondence to: Ivan Otterness, Ph.D., 241 Monu-
ment St. #5, Groton, CT 06340, U.S.A. Tel: 860-445-5369; E-mail:
otterx@earthlink.net
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Five microlitres of papain (26 mg/ml), prepared in 50 mM
phosphate buffer with 2 mM acetyl cysteine and 1 mM
EDTA, were added to 0.5 ml of water and the patella
digested for 1 h at 60°C. Synovial washings (approximately
100 l) were directly digested with 2 l of papain prior to
analysis. Biochemical analyses were done as detailed
previously.18
Briefly, primary amino acids were derivatized first
by the nonfluorescent OPA/MCE (o-phthalaldehyde/
mercaptoethanol), followed by derivatization of the
secondary amines hydroxyproline, sarcosine and proline
with FMOC (9-fluorenylmethyl chloroformate) and the
derivatized amino acids separated on a C18 column
(Kromasil, Column Engineering, Ontario, CA). The eluate
was monitored by fluorescence with excitation at 265 nm
and emission at 315 nm. The hydroxyproline peak was
corrected using sarcosine as an internal standard.
The sample was passed through a 30×0.78 cm TSK-
GEL G5000PWXL column (TosoHass, Montgomeryville,
PA, U.S.A.) and the column effluent monitored at 206 nm.
The first high molecular weight peak was hyaluronan. The
sample was mixed post column with a solution containing
16 mg DMMB, 3.04 gm glycine, 2.37 gm sodium chloride,
and 1.58 ml 6N HCl in 1 l, and the amount of proteoglycan
read at 540 nm. Hyaluronan and chondroitin sulfate (Seika-
gaku America, Rockville, MD, U.S.A.) were used as a
standards for quantitation.WESTERN BLOTS
In a 500 l Eppendorf tube, 50 l Laemmli sample buffer
was added to synovial fluid, stripped cartilage or intact
patellas, the pH was adjusted to basic and the sampleACTIVATION OF COLLAGENASE
Recombinant MMP-13 (1 mg/ml) was activated immedi-
ately prior to use by incubating with 0.1 M p-aminophenyl
mercuric acetate (APMA; Sigma, St Louis, MO, U.S.A.) at
37°C for 80 min. After placing on ice, the MMP-13 was
diluted for use with normal saline. Activation was confirmed
by SDS PAGE gel electrophoresis and activity confirmed
with TNO211. Activated enzyme was used immediately. In
some experiments, MMP-1 was similarly activated, except
that an incubation time of 60 min was used.ANIMAL HOUSING
Female golden Syrian hamsters (Mesocricetus auratus)
strain LAK.LVG(SYR) were purchased from Charles River
Laboratories (Kingston, NY, U.S.A.) at 100–110 g weight.
They were maintained on a 10/14 h light/dark cycle with
food and water ad libitum, and were acclimatized for at
least 1 week in standard housing before studies were
initiated. Central Research-Groton’s laboratory animal care
and use programs and facilities have been fully accredited
by the Association for Assessment and Accreditation
of Laboratory Animal Care, International (AAALAC
International). These studies were reviewed and approved
by the Institutional Animal Care and Use Committee
(IACUC) prior to the start of the study.IN VITRO INDUCTION OF CARTILAGE DEGRADATION
Patellas from control hamsters were removed after
sacrifice by anaesthesia overdose and collected in RPMI
media (Life Technologies, Grand Island, NY, U.S.A.) on ice.
Under a dissecting microscope, the cartilage was stripped
off the patellar bone and separated from the loose connec-
tive tissue after incubation in 5% formic acid at 37°C for 1 h.
Cartilages were placed individually in wells of a 96-well
plate and washed with PBS three times. Two hundred
microlitres of APMA-activated MMP-13 at 5 g/ml were
added to each well. The plate was incubated for 3 h at
37°C. The supernatants were transferred to clean plates
and frozen until assayed. Cartilage pieces were transferred
to 500 l Eppendorf tubes and frozen until assayed. In
some experiments, the intact patellas were incubated with
MMP-1 under the same conditions. The cartilage was then
stripped from the patella, frozen and assayed.IN VIVO INDUCTION OF CARTILAGE DEGRADATION
Groups of six hamsters were anesthetized with sodium
pentobarbital (80–100 mg/kg i.p.). The treatment groups
received intraarticular injections of 20 l of activated
MMP-13 in saline into the synovial cavity of both hind knees
using a 30 gauge needle. At various times after injection,
hamsters were sacrificed by pentobarbital overdose, and
synovial fluids collected from each knee by lavage (three
times with 15 l saline) and pooled for each animal. Patel-
las were taken for biochemical analysis and cartilage
obtained as above. Both cartilage and joint lavage fluids
were analysed by Western blot or assayed for hydroxypro-
line, proline, hyaluronic acid, proteoglycans or neoepitope.IMMUNOHISTOCHEMISTRY
Hind limbs were fixed overnight in 10% neutral buffered
formalin (4°C). The knees were then decalcified for 72 h inKristensen’s solution, rinsed for 24 h with cold tap water,
trimmed laterally across each long bone, sagitally bisected
with a razor blade, and embedded in Paraplast Plus
(Oxford Labware, St Louis, MO, U.S.A.). The knees were
mounted to allow 5-m sagittal sections (Reichertt-Jung
Autocut microtome) to be cut from the medial to the lateral
surface of the medial femoral condyle, with sectioning
beginning perpendicular to the medial side of the knee.
Slides were blocked with ovalbumin, stained with 9A4
antibody, donkey anti-mouse alkaline phosphatase, and
developed with BCIP/NBT Phosphate Substrate System
(Kirkegaard & Perry Laboratories, Gaithersburg, MD,
U.S.A.), rinsed and air-dried.TNO211 FLUORESCENT ASSAY FOR MMP-13 ACTIVITY
The peptide substrate, TNO211 (Dabcyl-Gaba-Pro-Gln-
Gly-Leu-Glu(EDANS)-Ala-Lys-NH2)17 was used to detect
MMP activity in synovial fluid from the hamsters. Thirty
microlitres of buffer (50 mM Tris, pH 7.6, 150 mM NaCl,
5 mM CaCl2, 1 M ZnCl2, 0.01% Brij) was added to 20 l of
a dilution of synovial fluid lavage sample in wells of a
96-well tissue culture plate. To this, 50 l of 2 M TNO211
substrate in assay buffer was added. A CytoFluor multi-well
plate reader (Perseptive Biosystems, Framingham, MA,
U.S.A.) was used to determine fluorescence (excitation at
360 nm and emission at 490 nm) at 5 min intervals. A
standard curve with MMP-13 was generated and fluor-
escence units translated into ng/ml of MMP-13.
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samples were added to each lane of polyacrylamide
4–20% multigels, ISS mid range prestained molecular
weight markers (Integrated Separation Systems, Natick,
MA, U.S.A.) were added and the gel run in Seprabuff
(TRIS, glycine, SDS) buffer for approximately 1.5–2 h. Gels
were transferred onto nitrocellulose overnight. Blots were
blocked with 1% nonfat dry milk in PBS, probed with 9A4 or
5109 monoclonal antibodies, and developed with the BCIP/
NBT Phosphatase Substrate System (Kirkegaard & Perry
Laboratories, Gaithersburg, MD, U.S.A.), rinsed and air-
dried.RATE OF CLEARANCE OF MMP-13 FROM SYNOVIAL FLUID
After intraarticular injection of MMP-13 into the hamster
knee, the synovial fluid was lavaged at several time points
and measured with TNO211 substrate for MMP-13 activity.
The activity was plotted against time and normalized to ng
of the freshly activated MMP-13 (Fig. 2). Since 10 g of
MMP-13 was injected in 20 l saline, the concentration at
the time of injection in the joint should have been 500 g/
ml. Extrapolating back to time zero, we recovered only
200 ng/ml by activity measurements. As the lavage fluids
were diluted 60 fold [Fig. 2(b)], approximately 98% of the
activity was removed. The residual activity was cleared with
a half-life of 2 h. Since that activity is potentially made up of
free enzyme and enzyme complexed to 2-macroglobulin,
the substrate TNO211 was coupled to ovalbumin to block
its penetration into the serpin cage of 2-macroglobulin.
About half of the activity remained against OVA-TNO211.
That activity was cleared at a half-life of 1.8 h.ELISA FOR TYPE II COLLAGEN NEOEPITOPE
Monoclonal antibody (9A4) in 0.05 M sodium borate
buffer (pH 8.5) was added to 96-well plates (Nunc
Maxisorb, VWR, Boston, MA, U.S.A.) and incubated for
18–48 h at 4°C. After washing three times with Dulbecco’s
phosphate buffered saline containing 0.05% Tween-20
(PBS/tw), plates were blocked with 1% non-fat dry milk in
PBS (NDM) for 1 h at 22°C. After washing plates once with
PBS/tw, peptide 130 (GEPGDDAPSGAEGPPGPQG) in
0.1% NDM was diluted for a standard curve. Unknown
synovial fluid samples were diluted 1:5 in 0.1% NDM and
plated in duplicate. Plates were incubated for 1 h at 37°C.
After washing three times with PBS/tw, biotinylated anti-
body 5109 (100 l of 1 g/ml) was added to appropriate
wells and incubated for 40 min at 37°C. Unbound bio-
tinylated antibody was removed by three washings with
PBS/tw; mouse monoclonal anti-biotin antibody coupled
with horseradish peroxidase (Jackson ImmunoResearch,
West Grove, PA) diluted 1:5000 was added to the wells and
the plate incubated at room temperature for 30 min. After a
final 3× wash, 3,3′5,5′-tetramethyl benzidine (1-step Turbo
TMB-ELISA; Pierce, Rockford, IL) was added and the plate
incubated at room temperature for approximately 10 min to
develop the color. The color reaction was stopped with 2 N
H2SO4 and the plate read on a spectrophotometer at
450 nm. Neoepitope was determined from the peptide 130
standard curve.Results
FRAGMENTS GENERATED FROM CARTILAGE BY MMP-13 IN VITRO
Cartilage from patellas was incubated with MMP-13
in vitro, and Western blotting performed on the digested
sample. We have previously shown that monoclonal anti-
body 9A4 detects the circa 110 kD 3/4 piece by reacting
with the C-terminal MMP-13 generated neoepitope in
cartilage.10,14 In supernatants from the 3 h 37°C incubation
of cartilage with MMP-13 activated by APMA, the 9A4
reactive collagen fragments were of much lower molecular
weight (Fig. 1). A band of approximately 32 kDa was seen
with a very faint trace at 23 kDa (lane 1). To clarify the
staining pattern a second monoclonal antibody, 5109, was
used. 5109 recognizes an epitope only three residues
N-terminal to the 9A4 epitope in type II collagen, but does
not recognize type I collagen.16 Staining with 5109 (lane 3),
a far more sensitive antibody, showed a dominant 32 kDa
fragment and a moderately strong 23 kDa fragment. In
addition, two weaker bands could be seen at 70 kDa and
42 kDa (very faint) that were not observed when this gel
was stained by 9A4.As a further control, the whole patella with attached
synovial lining, ligaments, bone and soft tissue was incu-
bated with collagenase and the supernatants examined by
Western blot. Now, 9A4 staining (lane 2) showed four
bands: two faint bands at 26 and 30 kDa, a doublet at
31 kDa and an intense band at 38 kDa, consistent with its
staining collagenase-cleaved type I collagen. None of the
bands overlapped with the bands from digested articular
cartilage (lane 1 or lane 3). Staining of a parallel blot with
5109 showed the presence of a type II collagen band (lane
4) at 32 kDa coincident with the bands observed with the
cartilage supernatant (lanes 1 and 3) and the absence of
the four type I collagen bands detected by 9A4.Fig. 1. Detection of MMP-13 cleavage products in supernatants of
hamster patella with attached tendons (lanes 2 and 4) and isolated
patellar cartilage (lanes 1 and 3) after incubation of tissue with
APMA activated MMP-13 for 3 h. Staining with the neoepitope
antibody 9A4 (lanes 1 and 2) and with the type II collagen specific
antibody 5109 (lanes 3 and 4). Lane 1 shows a 32 kDa band and
a very faint trace of a 23 kDa band; lane 2 shows 26, 30, 31 and
38 kDa bands, lane 3 shows 23, 32, 42 and 70 kDa bands and lane
4 shows a 32 kDa band.
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CARTILAGE
Activated MMP-13 was injected into the hamster knees,
and 2 h later the cartilage was collected and processed for
immunohistochemistry. Cartilage sections were stained for
the collagenase cleavage neoepitope with monoclonal anti-
body 9A4 (Fig. 3). In the absence of MMP-13, no staining
was observed in any of the tissues. In MMP-13-injected
knees, a superficial staining band less than 1 micron thick
was observed on the articular cartilage. Neoepitope stain-
ing was observed passing more deeply into the synovial
lining and into the meniscus, but in no case did the
cleavage occur deeply, i.e. beyond the superficial
2 microns.
When the cartilage was recovered after intraarticular
MMP-13 injection, run on a gel and transferred for Western
analysis with antibody 9A4, only a single band consistent
with the 3/4 piece was observed in the cartilage (Fig. 4,
lane 1). When an MMP-13 digested cartilage was heavily
loaded (lane 2), the 3/4 piece and still higher molecular
weight fragments were seen. Presumably, this reflects
cross-linked, cleaved fragments. No staining was observed
when cartilage was taken from a normal animal (lane 3).
For comparison, 10 g MMP-1 was injected into the knee
joint (lane 4). The same molecular weight band was
obtained as with MMP-13, except generally MMP-1 gave
more intense staining.MEASURES OF CARTILAGE DAMAGE IN THE SYNOVIAL FLUID
Initial experiments using the neoepitope ELISA were
carried out in vitro. Cartilage was incubated with MMP-13
and, at different times, o-phenanthroline was added to stop
digestion. The supernatants were taken and both the
amount of hydroxyproline and the amount of neoepitope
were measured. Both hydroxyproline and the neoepitope
were released linearly with time (Fig. 5).
Next, the amount of neoepitope released into the
synovial fluid 2 h after the intraarticular injection of 1, 3 and
10 g of MMP-13 was measured by ELISA. A dose depen-
dent increase of neoepitope in the synovial fluid lavage was
found (Fig. 6), with the range of release from 0.45 nM of
neoepitope at 1 g of MMP-13 to 1.45 nM at 10 g.
The concentration of hydroxyproline, hyaluronan, GAGs
and neoepitope in the synovial fluid with or without intra-
articular MMP-13 was measured. The results are shown in
Fig. 7. Of the four biochemical measures, only theneoepitope was undetectable in normal synovial lavage
fluid. It gave the largest and the most specific signal for
MMP-13 activity. For comparison, MMP-1 was also injected
intraarticularly at 10 g/ml. Both hydroxyproline and
hyaluronan essentially doubled with MMP-13, but hardly
increased with MMP-1. Both GAGs and the neoepitope
were significantly increased with MMP-1, but the magni-
tude of the increase was much less for MMP-1 than with
MMP-13.
We examined GAG release by MMP-13 in more detail by
determining its release over time (Fig. 8). After the initial
increase in GAGs within the first half-hour, no significant
change in GAG levels was seen with time. There was no
evidence of GAG clearance or increased production of
GAGs.
The release of the neoepitope into the synovial fluid after
MMP-13 was not time-dependent (Fig. 9). After an initial
increase in neoepitope at 0.5 h, the amount of neoepitope
in the synovial fluid decayed with a half-life of about 1.8 h.
Western blots using antibody 9A4 failed to detect
collagen fragments in the synovial fluid after MMP-13
injection (Fig. 10). However, when the samples were
stained with 5109, a 32 kDa band was observed which
exactly coincided with the type II collagen fragment found in
cartilage supernatants after in vitro digestion with MMP-13
(Fig. 1, lanes 3 and 4).Discussion
To gain some understanding of the effects of MMP-13
in vivo, we injected it into hamster knee joints and first
determined its fate. We used an activity assay with the
substrate TNO211 to measure the sum of free and
2-macroglobulin-inactivated MMP-13 in synovial fluid;
TIMP-inactivated MMP-13 would not be observed in this
assay.19 Activity measurements showed that 98% of
MMP-13 activity was cleared from the joint before our first
measurement. We do not know its disposition.
The MMP-13 activity that remained in the synovial fluid
was cleared with a half-life of circa 2 h. Based on determi-
nations made in human synovial fluid, the bulk of the
enzyme would have been expected to be inactivated by
2-macroglobulin.19 We tested that hypothesis by using
TNO211 coupled to ovalbumin, a large substrate that
cannot penetrate the serpin cage of the 2-macroglobulin.
Based on that substrate, we estimated that only about half
of the residual MMP-13 was captured by 2-macroglobulin.
The hamster has only a microliter of synovial fluid,18 so ifFig. 2. Determination of active MMP-13 in the hamster knee joint. MMP-13 was assayed in synovial lavage fluid at 0, 0.5, 1, 2, 3 and 4 h after
intraarticular injection of 10 g in 20 l of activated MMP-13. (a) The fluorescent substrate TN0211 () or TN0211 coupled to ovalbumin (")
was used to determine the residual MMP-13 activity at each time point. (b) The data from (a) are shown in a log plot with the best fit line.
For substrate TN0211, the t1/2=2.0 h. For substrate TN0211-OVA, t1/2=1.8 h.
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human concentration, the capacity of the 2-macroglobulin
was simply overwhelmed.
The antibody 9A4 was used to immunolocalize sites
of collagen cleavage by MMP-13. Not surprisingly, the
collagen cleavage was also localized to the superficial layer
of cartilage and soft tissue. Most interestingly, there was noevidence of more than limited superficial penetration of
either tissue. This was consistent with our in vitro studies20
in which MMP-1 and MMP-13 were compared. MMP-1
autolysed at two sites, thereby separating the hemopexin
domain from the catalytic domain, i.e. within the QPIG andFig. 3. Localization of sites of collagen cleavage by collagenase
2 h after intraarticular injection of 10 g of MMP-13. All sections
stained with monoclonal antibody 9A4. (a) Control uninjected joint.
(b) Articular cartilage staining after MMP-13 injection. (c) Synovial
lining staining after MMP-13 injection.Fig. 4. Western analysis using monoclonal antibody 9A4 of the
collagen fragment found in cartilage after intra-articular MMP-13.
Cartilage from a knee intra-articularly injected with 10 g activated
MMP-13 (lane 1), articular cartilage cleaved by MMP-13 in vitro
and heavily loaded (lane 2), cartilage from a control knee (lane 3),
cartilage from a knee intra-articularly injected with 10 g activated
MMP-1 (lane 4).Fig. 5. Comparison of the release of the collagenase-cleavage
neoepitope and of hydroxyproline with time from isolated hamster
patellar cartilage in vitro. Patellar cartilage was incubated with
5 g/ml of activated MMP-13. At the appropriate time intervals, the
supernatants were removed from the cartilage and analyzed for
neoepitope (h) and hyproxyproline (m). Three separate analyses
were made at each time point.Fig. 6. Effect of the concentration of intraarticularly injected
MMP-13 on the release of the collagenase-cleavage neoepitope
into the synovial fluid. Synovial fluid was collected 2 h after
MMP-13 injection. No neoepitope was detected in the absence of
MMP-13.
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circa 1.0 mm over 24 h. MMP-13 did not autolyse and failed
to penetrate beyond the top 50 m of the cartilage over the
same time period. This difference is best explained by the
strong binding of the hemopexin domain for collagen
and gelatin.22 Unless there are other enzymes such as
gelatinase present that can complete the destruction of the
binding ligand, the enzyme remains tethered to residual
collagen.
When the cartilage was directly incubated with MMP-13
in vitro and the cartilage examined by Western analysis,
the lowest molecular weight and dominant band was
110 kDa, consistent with the 3/4 piece. Higher molecular
weights, presumably cross-linked fragments, were also
often seen. By contrast, in the culture fluid from the
MMP-13 digested cartilage we noted only smaller frag-
ments, suggesting that additional cleavage is required for
release of the neoepitope. When we examined the cartilage
after exposure with MMP-13 or MMP-1, consistent with our
in vitro results, only the 3/4 piece fragment was found. By
contrast, only small neoepitope fragments were found in
the synovial fluid. This suggests that after the first clip of
type II collagen, the 3/4 piece was retained in cartilage,
perhaps by the N-terminal pyridinoline cross-links. Thus we
observed only the 3/4 fragment in cartilage. MMP-13 is also
known to clip type I collagen just after the C-terminal
crosslink23,24 at the sequence KSAG↓VSVPGP. By struc-tural homology, it could potentially cause a clip in type II
collagen in that region. However, in the supernatant we
failed to see appearance of a 3/4 size piece; only smaller
fragments were seen in the fluid phase, whether in vitro or
in vivo. Thus an additional cleavage appears be required to
free the neoepitope-containing fragment, implying that
MMP-13 must cleave at additional central sites. There are
two other collagenase-like cleavage sites, both of structure
GPPGPQG↓ARG, giving potential cleavages between
G92-A93 and G413-A414, resulting in 29 kDa and 34 kDa
fragments calculated from the amino acid sequence.
Fragments of 32 and 42 kDa were found on our gels,
consistent with the observation that collagen and its frag-
ments run at higher apparent molecular weight than the
amino acid sequence would predict. Although, in this case,
the cleavage releasing the neoepitope was accomplished
by MMP-13, obviously the neoepitope could be released by
concerted attack with other enzymes such as gelatinase,
stromelysin or plasmin after the denaturation of the helix.
MMP-1 showed a reduced ability to cleave type II collagen
and did not cleave the cross-link site of type I collagen. This
probably explains the more intense staining of the 3/4 piece
in cartilage.
We developed an ELISA to measure collagenase-
cleaved type II collagen fragments.16 A surviving intact
piece of 18 amino acids, which includes the neoepitope, is
all that is required for detection of the release of the
neoepitope fragment from the 794 amino acid 3/4 piece.
We found synovial lavage fluid to contain a large amount of
the type II collagen cleavage fragments within half an hour
of the intra-articular injection. Our Western data suggested
that the enzyme initially bound and caused a single cleav-
age of type II collagen at the traditional cleavage site, since
only the 3/4 fragment could be detected in the cartilage,
while additional clips released the neoepitope into synovial
fluid. The collagen fragments in the synovial fluid appeared
to be cleared from the synovial fluid with a t1/2 of 1.8 h.
5109 data suggested that the major fragment is 32 kDa.
Based on our human studies, type II collagen fragments
enter the circulation and later appear in the urine where
they can be measured by this ELISA.16
We also examined several measures of collateral dam-
age by MMP-13. First, in synovial lavage fluid, there was an
elevation of hydroxyproline. This elevation was only an
incidental contribution by the type II fragments measured
by ELISA. If we used a crude patellar tissue preparation
(containing ligament, tendon and loose connective tissue
fragments), we found a set of small collagen fragments
containing neoepitope that were distinct from type II
collagen fragments. Presumably, they are largely type I
collagen fragments from menisci and tendon. It is likely that
the majority of the hydroxyproline elevation comes from
such type I collagen fragments. Moreover, the release of
these collagen fragments continued after the release of
type II collagen fragment had ended. This is supported by
the deeper penetration of the loose connective tissue than
the cartilage on staining with 9A4, the presence of type
I-like fragments in synovial fluid (data not shown), and the
continuing release of hydroxyproline over time.
We carried out a few comparisons of MMP-13 with
MMP-1. MMP-1, like MMP-13, left evidence of only the 3/4
piece in the cartilage after the intra-articular injections, but
MMP-1 appeared to result in more 3/4 piece in the carti-
lage. MMP-13 can clip collagen in the cross-link region and
has good gelatinase activity. Therefore, it can presumably
release the 3/4 piece and its fragments from cartilage much
more readily. Across the board, MMP-1 released lessFig. 7. Biochemical products in synovial fluid in control knees ( )
or knees injected with either activated MMP-1 (h) or MMP-13 (").
To place all values in the same scale, the following units are used:
hydroxyproline (nM), hyaluronic acid (mg/ml ×100), GAGs (g/ml
×10), collagenase-cleavage neoepitope (nM ×10).Fig. 8. GAGs in synovial fluid with time after MMP-13 injection.
MMP-13 was injected at time=0 and the synovial fluid collected by
lavage at the indicated time points. GAGs were quantitated after
papain digestion and passage through a HPLC sizing column.
GAGs were the high molecular weight material that stained with
dimethylmethylene blue. Levels of GAGs prior to injection of
MMP-13 (), level of GAGs post-MMP-13 injection (").
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and less neoepitope into the synovial fluid. This may reflect
the greater collagenolytic activity of MMP-13 against type II
collagen.
Assuming that the GAGs, like the collagen, were
produced in the first half-hour and then rapidly cleared, we
sought to measure a clearance rate. We found that the
GAGs were not significantly cleared. Page-Thomas et al.25
reported a clearance rate of 12 h for injected aggrecan
monomers whether or not they could aggregate. By con-
trast, after intraarticular IL-1 injection, we found a clearancerate of close to 8 h in the hamster (Otterness et al.,
unpublished data). The clearance we measured with GAGs
released by IL-1 is presumably due to cleavage of
the intraglobular domain by aggrecanase. MMP-13 is
reported to cleave aggrecan in the intraglobular domain.11
Presumably, if it did so here, it would also be cleared at a
rate comparable to IL-1 released aggrecan rather than at
the slower rate observed here. Therefore, we suggest that
in this model, aggrecan is released nonspecifically as a
result of collagen network breakdown and comes out as
the large aggrecan complex, that is, with HA, aggrecan
monomer and link protein reasonably intact.
In OA, MMP-13 would presumably be produced in latent
form by the chondrocyte and activated by another locally
produced enzyme. Nonetheless, although injection of the
MMP-13 into a joint is an artificial situation, several of the
results appear to have general applicability to MMP-13
in situ. First, MMP-13 will be constrained to act very locally,
i.e. probably just in the intraterritorial domain of the
chondrocyte. To digest collagen at a site further removed, it
would need additional helper enzymes to destroy any
residual sites that could bind its hemopexin domain and
thus limit diffusion. Alternatively, it would require a second
protease to proteolytically separate its hemopexin domain
from its catalytic domain. This would allow diffusion through
the cartilage as happens with MMP-1. Second, essentially
all of the MMP-13 injected is instantaneously removed from
the synovial fluid, suggesting that it is highly unlikely there
is any free MMP-13. The tissue is essentially a large sink
for MMP-13, and 2-macroglobulin and the TIMPs are
normally around to mop up any residual free MMP-13.
Third, primary cleavage of collagen at the 3/4 piece site
appears to fail to release collagen fragments into the
synovial fluid. Cleavage at secondary sites within the 3/4
piece leads to release of the neoepitope. Outside cartilage
we found a dominant 32 kDa fragment; however, the frag-
ment size obtained under conditions where other enzymes
are present and MMP-13 is limiting may be different.
Fourth, once these small fragments of collagen diffuse into
the synovial fluid, they are rapidly cleared. Finally, these
released collagen fragments can be used to monitor colla-
gen damage. Although we have demonstrated in this paper
that we can measure collagen fragments in synovial fluid of
animals, we have also carried out similar measurements in
synovial fluid (unpublished observations) and in the urine of
OA patients.16
In summary, activated MMP-13 leads to tissue collagen
damage with the release of collagen fragments. TheseFig. 9. Time-dependent release of the collagenase-cleaved collagen neoepitope fragments after MMP-13 intraarticular injection. (a) Amount
of neoepitope in the synovial fluid with time after MMP-13 injection. (b) The same data plotted in (a) in a logarithmic scale, and is fitted to
a linear equation. The t1/2 (1.8 h) for clearance was calculated on the assumption that there is no further significant production of neoepitope
after the first half-hour.Fig. 10. Detection of type II collagen fragments in synovial fluid
after MMP-13 injection. MMP-13 injected knee synovial lavage
fluid (lane 1); control knee synovial lavage fluid (lane 2). Staining
on Western analysis using monoclonal antibody 5109.
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